CD8A and cancer: The blood concentration of MDSCs could be good prognostic markers for overall survival after 2 years in refractory diffuse large B-cell lymphoma [21]. In addition, tumors responding to ICIs therapy tend to have higher CD8+ T cells and fewer Gr-1+CD11b+ MDSCs at the early stage following therapy initiation in the mouse model [26]. Furthermore, in patients with different cancer types who received ICIs, the circulating and tumor-infiltrating myeloid populations can be used as predictive biomarkers, both at baseline and on treatment [27].